Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$15.24
▼ $0.25 (-1.6%)
Market data updated: 09/20 06:16 AM
News analyzed: 09/20/2026
Market Cap
$1.34B
Day Range
$15.10 - $15.63
52-Week Range
$3.43 - $15.79
Beta
—
Next Earnings
—
Support
$10.96
Resistance
$15.79
DRTS is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+300.0% (1Y)
🟡 Moderate
Strengths: 8/13 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟢 Bullish
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Price vs. SMA 50
Price is above the 50-day average
Technical
Biggest negative driver
Daily volatility (ATR)
ATR: 4.5% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
DRTS demonstrates a nuanced technical and risk profile, with its **investorScore of 78** and **STRONG** rating primarily driven by strong technical momentum and positive news sentiment. The stock sits above both its 50-day and 200-day moving averages, signaling sustained uptrend strength, while an **RSI of 64.0** and **ADX of 28.2** further validate a healthy upward momentum. However, the **MACD histogram’s negative reading** and **overbought %K (90.8)** introduce caution, suggesting potential short-term exhaustion. News sentiment is overwhelmingly positive, with Barclays’ **overweight rating and $30 price target** and Alpha Tau’s clinical milestones reinforcing investor confidence. Risk metrics, however, are a notable drag: the **ATR of 4.5%** and **Kalmár ratio of 1.34** (indicating a 64.8% annualized return but a 48.3% max drawdown) highlight volatility and downside risk, tempering the overall outlook.
The stock exhibits clear bullish momentum with prices above both the 50-day and 200-day moving averages, an RSI of 64.0, and an ADX of 28.2, but the MACD histogram is negative, and the %K is overbought at 90.8.
These indicators suggest a strong uptrend with potential for consolidation or reversal due to overbought conditions.
Recent news is overwhelmingly positive, including Barclays’ overweight rating, a raised price target, and Alpha Tau’s clinical progress announcements.
Positive news sentiment strengthens investor confidence and could drive further upward movement.
The ATR stands at 4.5% of the stock price, and the Kalmár ratio indicates a high volatility profile with a 48.3% maximum drawdown over three years.
These metrics signal significant volatility and potential downside risk, which could impact short-term stability.
StockIQ conclusion
DRTS presents a mixed picture, with strong technical indicators and positive news sentiment supporting its STRONG rating, but notable risks from volatility and overbought conditions temper the outlook. The stock’s ability to sustain momentum depends on maintaining investor confidence amid potential pullbacks, while clinical and regulatory developments remain pivotal for long-term stability.
Written automatically from the computed data shown on this page only — not investment advice.
🗓️ What Changed This Week
as of 09/10/202681
This Week
70
7D Ago
↑ +11
Improving
Technical
81
7D Ago: 63
↑ +18
News
100
7D Ago: 100
→ 0
Risk
42
7D Ago: 42
→ 0
Biggest Improvements
📊 Score History
81
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
today · $15.24
Evidence: 8 bullish / 1 bearish technical signals agreeing
What happened after
Still awaiting outcome
1d ago · $15.49
Evidence: Euphoria score crossed 55 (now 60)
What happened after
Still awaiting outcome
1d ago · $15.49
Evidence: FOMO score jumped from 12 to 50 day-over-day
What happened after
Still awaiting outcome
15d ago · $15.03
Evidence: FOMO score jumped from 22 to 47 day-over-day
What happened after
16d ago · $14.62
Evidence: 1.5x recent average volume
What happened after
16d ago · $14.62
Evidence: 8 bullish / 2 bearish technical signals agreeing
What happened after
22d ago · $14.60
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
22d ago · $14.60
Evidence: 10 bullish / 1 bearish technical signals agreeing
What happened after
23d ago · $14.81
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
23d ago · $14.81
Evidence: 10 bullish / 1 bearish technical signals agreeing
What happened after
24d ago · $15.00
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
24d ago · $15.00
Evidence: 10 bullish / 1 bearish technical signals agreeing
What happened after
25d ago · $14.70
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
25d ago · $14.70
Evidence: 10 bullish / 1 bearish technical signals agreeing
What happened after
🐂🐻 Investment Thesis
🐂 Bull Case
⚖️ Base Case
81 / 100
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🕰️ StockIQ Time Machine
What did StockIQ know — and when? Pick a date from the real accumulated history.
As of August 26, 2026
Then
85
$14.70
Now
81
$15.24
What happened since
Signals detected by this date
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
No data available
Quality
No data available
Value
No data available
Momentum
81
Risk
42
Sentiment
100
Fundamental
No data available
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **Alpha Tau Medical Ltd.** has focused on its **Alpha DaRT®** alpha-radiation cancer therapy, particularly its **pivotal clinical milestones**. The company completed enrollment in its **IMPACT pancreatic cancer study**, expanding from 12 to 48 patients due to high demand, highlighting its potential as a one-time add-on to chemotherapy. Analysts, including Barclays, have raised price targets, signaling optimism ahead of **upcoming glioblastoma (GBM) and pancreatic cancer data**. The company is also engaging with investors at key conferences in September 2026.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Alpha Tau Medical Ltd.. News trend score: 100. Reason: 11 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
49
🎯 Conviction (vs. Emotion)
50
Psychology
63
Fundamentals
—
Technical
81
Valuation
—
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price (3M)
+56%
Market Narrative
75
Fundamental Reality
50
Narrative Gap
+25
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market’s fixation on the 0.9% resistance gap dominates behavior, suggesting traders are anchoring to this near-term target despite euphoric momentum and extreme sentiment. The narrative-reality gap (19) hints at overconfidence in bullish narratives, while peer underperformance limits herd-driven buying. The key question: will traders break the resistance anchor, or will euphoria sustain momentum despite overvaluation?
Updated: 09/08/2026, 03:43 PM
What could change this?
👥 What the crowd believes
"Barclays analyst raises price target from $17 to $30"
"IMPACT study expanded enrollment three times to 48 patients due to demand"
"Pounding the table on potential GBM breakthrough data"
🧠 Market Brain events driving this
📈 16D Investor Psychology
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Jesse Livermore — 58/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
The stark contrast between the methodologies highlights a deep divide in how they interpret DRTS’s market behavior. Burton Malkiel and John Bogle’s efficient-market approach gives it a relatively high score, suggesting the stock’s movement aligns with broader market logic—perhaps reflecting a justified deviation from passive indexing. Meanwhile, the majority of value-oriented investors like Graham, Fisher, and Lynch can’t even form a verdict due to insufficient data, leaving their models neutral. On the other end, risk-averse and cycle-sensitive strategists—from Gerald Loeb to Morgan Housel—pile on warnings, flagging it as speculative, overbought, or volatile, with Housel’s near-zero score implying it’s a classic candidate for panic-driven selling. The divergence underscores whether DRTS is a rational market anomaly (to Malkiel/Bogle) or a speculative bubble (to Marks, Loeb, or Housel), with no middle ground for fundamentalists due to data gaps.
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟢 71
A real, well-supported case — deviating from a broad index may be justified here
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 58
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 50
Not enough balance-sheet/valuation data for a real Graham read
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Peter Lynch
One Up on Wall Street (1989)
🟡 50
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Walter Bagehot
Lombard Street (1873)
🟡 50
Not enough balance-sheet data for a real Bagehot read
Key question
Does this company have enough liquidity to survive real stress?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 50
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 31
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 26
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🔴 24
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 21
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 20
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 19
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 16
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (8 bullish · 1 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Sentiment based on basic keywords (not AI) — 11 positive, 7 neutral, 2 negative out of the last 20 articles.
SeekingAlpha · 11.9.2026
SeekingAlpha · 4.9.2026
Benzinga · 3.9.2026
Yahoo · 2.9.2026
GlobeNewswire · 2.9.2026
MT Newswires · 31.8.2026
Yahoo · 31.8.2026
GlobeNewswire · 31.8.2026
Yahoo · 28.8.2026
Zacks Small Cap Research · 28.8.2026
GlobeNewswire · 17.8.2026
Benzinga · 11.8.2026
GlobeNewswire · 10.8.2026
Benzinga · 10.8.2026
MT Newswires · 10.8.2026
Simply Wall St. · 1.8.2026
Benzinga · 22.7.2026
GlobeNewswire · 21.7.2026
Yahoo · 21.7.2026
Benzinga · 21.7.2026
StockIQ doesn't currently have enough real data to compute a reliable score for Alpha Tau Medical Ltd. (DRTS) — only 3 of 7 categories are available right now. Rather than show a misleading number, this page shows which data is missing instead.
StockIQ doesn't give buy/sell recommendations — and for DRTS specifically, there currently isn't enough real data (only 3 of 7 categories available) to state even a factual score reliably. Check back once more data is available.
DRTS's technical score is 81/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Price is above the 50-day average; Price is above the 200-day average; MACD histogram is positive — rising momentum.
Based on the real signals StockIQ computed: ATR: 4.5% of price; CMF 20 days: -0.15.
StockIQ has no recorded dividend payment history for DRTS.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 15 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Levy Raphi | Exercise of Derivative Securities | 21.8.2026 | 93,051 | +2,871 | $2.98 |
| Levy Raphi | Open Market Sale | 21.8.2026 | 90,180 | -2,871 | $15.00 |
| Levy Raphi | Open Market Sale | 21.8.2026 | 2,871 | -2,871 | $15.00 |
| Levy Raphi | Exercise of Derivative Securities | 21.8.2026 | 2,871 | +2,871 | $2.98 |
| Levy Raphi | Open Market Sale | 11.8.2026 | 17,730 | -17,730 | $14.00 |
| Levy Raphi | Exercise of Derivative Securities | 11.8.2026 | 17,730 | +17,730 | $2.98 |
| Levy Raphi | Open Market Sale | 11.8.2026 | 90,180 | -17,730 | $14.00 |
| Levy Raphi | Exercise of Derivative Securities | 11.8.2026 | 107,910 | +17,730 | $2.98 |
| Levy Raphi | Exercise of Derivative Securities | 6.7.2026 | 2,270 | +2,270 | $2.98 |
| Levy Raphi | Open Market Sale | 6.7.2026 | 2,270 | -2,270 | $14.00 |
| Levy Raphi | Exercise of Derivative Securities | 6.7.2026 | 92,450 | +2,270 | $2.98 |
| Levy Raphi | Open Market Sale | 6.7.2026 | 90,180 | -2,270 | $14.00 |
| Levy Raphi | Open Market Sale | 2.7.2026 | 17,873 | -17,873 | $13.00 |
| Levy Raphi | Exercise of Derivative Securities | 2.7.2026 | 17,873 | +17,873 | $2.98 |
| Levy Raphi | Exercise of Derivative Securities | 2.7.2026 | 108,053 | +17,873 | $2.98 |
| Levy Raphi | Open Market Sale | 2.7.2026 | 90,180 | -17,873 | $13.00 |
| Levy Raphi | Open Market Sale | 1.7.2026 | 2,127 | -2,127 | $13.02 |
| Levy Raphi | Exercise of Derivative Securities | 1.7.2026 | 2,127 | +2,127 | $2.98 |
| Levy Raphi | Exercise of Derivative Securities | 1.7.2026 | 92,307 | +2,127 | $2.98 |
| Levy Raphi | Open Market Sale | 1.7.2026 | 90,180 | -2,127 | $13.02 |
| Levy Raphi | Open Market Sale | 30.6.2026 | 20,000 | -20,000 | $12.00 |
| Levy Raphi | Open Market Sale | 30.6.2026 | 90,180 | -20,000 | $12.00 |
| Levy Raphi | Open Market Sale | 25.6.2026 | 4,222 | -4,222 | $11.00 |
| Levy Raphi | Open Market Sale | 25.6.2026 | 15,778 | -15,778 | $11.00 |
| Levy Raphi | Open Market Sale | 25.6.2026 | 125,958 | -4,222 | $11.00 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
3,092,873 shares short as of 2026-08-31 · vs. 3,208,323 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
63.9% of trading volume this week was short selling, vs. 63.0% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology